Following the adoption of the EU Strategy for COVID-19 Therapeutics, the European Commission’s Task Force for Industrial Scale-Up of COVID-19 Vaccines and Therapeutics is organising an EU matchmaking event on COVID-19 therapeutics on 12 and 13 July at 9am CEST.
Medicines for COVID-19 are still in the development phase. The aim of this event is to help accelerate the development of new and repurposed medicines for COVID-19 therapeutics at all stages and mobilise the EU pharma manufacturing capacity for their potential production.
The target group is the EU COVID-19 therapeutics value chain, starting with researchers and developers, through to manufacturing companies and representatives of hospitals. The providers of clinical trials services, equipment suppliers (e.g. vials, syringes, tubes etc.), funding providers and public procurers were also invited to take part in this event.
The event was kicked off by opening speeches of Commissioners Thierry Breton and Stella Kyriakides.
Commissioner Kyriakides, responsible for Health and Food Safety, said: “The EU is making good progress on vaccination with 50% of adults now fully vaccinated. But vaccines are not our only response to COVID-19. With the spread of variants and the resurgence of cases across the EU in recent weeks, the development of therapeutics is more necessary than ever."
Key objectives are to:
- Support the acceleration of the development and upscale of COVID-19 therapeutics production
- Enhance participation of EU companies in therapeutics value chains
- Speed up connections between therapeutics developers, investors and companies
- Help in retro-planning strategy for the current and future therapeutics production
You can find the Report from this matchmaking event attached at the bottom of this page.